Introduction
Heart failure (HF) represents one of the cardiovascular diseases with the worst rate of morbidity and mortality, and with the highest health care costs in the western world. In spite of best care practice, the 1-year-survival rate of patients with end-stage HF is less than 50%. 1 The adverse anatomic remodelling of the left ventricle (LV) leading to HF is characterized, at the molecular level, by a profound functional
alteration of several proteins and by a characteristic reactivation of the fetal cardiac gene expression program. 2 This alteration is not limited to protein-coding transcripts. The Encyclopedia of DNA Elements (ENCODE) project indicated that at least 80% of the genome is functional and is transcribed into protein coding RNAs (about 1.1-1.5% of the RNAs) and in a much larger quantity of non-coding, regulatory RNAs, arbitrarily divided into long (lncRNAs, >200 nt), and short (<200 nt) ncRNAs. 3 Several lncRNAs have been shown to be involved in specific physiological and pathological processes, 4, 5 as well as in cardiovascular diseases (CVDs). [6] [7] [8] [9] [10] Antisense (AS) lncRNA are transcripts emerging from the opposite strand of a coding-RNA region. For instance, BACE1-AS is transcribed from an intron of the b-secretase-1 (BACE1) gene in antisense direction, completely overlapping exon 6. 11 Interestingly, unlike many other antisense transcripts, BACE1-AS increases the stability of the BACE1 sense transcript. 11, 12 BACE1 has been at the centre of intensive research, since it is the key rate-limiting enzyme for the production of the b-amyloid peptide, involved in the pathogenesis of Alzheimer's disease. 13, 14 The most common b-amyloid isoforms are bamyloid 1-40 and 1-42, typically produced by cleavage that occurs in the endoplasmic reticulum or in the trans-Golgi network. 14, 15 Intriguingly, HF and Alzheimer's disease share similar non genetic effectors and risk factors, such as hypercholesterolemia and metabolic syndrome. 16, 17 Moreover, hypoxia, ischaemia, cellular stress can facilitate the increase of BACE1 levels. 13 Additionally, the plasma level of b-amyloid 1-40 is significantly increased in coronary artery disease, allowing the identification of patients at high risk for cardiovascular death. 18 Based on these indications, we tested BACE1-AS and BACE1 involvement in HF progression.
Methods

Patient selection and tissue collection
Left ventricle (LV) cardiac biopsies from patients affected by dilated hypokinetic ischaemic cardiomyopathy were harvested during Surgical Ventricular Reconstruction procedure performed as described previously. 19 For each patient, 2 biopsies were collected from the nonischaemic and dysfunctional remote myocardium: one was immediately immersed in RNAlater (Qiagen GmbH) and stored at 4 C for <24 h before RNA extraction, and the other one was fixed in 10% neutral buffered formalin and paraffin embedded for histological assays. HF patient characteristics are described in Table 1 . The control group was constituted by age-and sex-matched subjects, that died for causes different from stroke, ischaemia, or cachexia for chronic diseases (n = 17, females/ males = 6/10; 58.3 ± 3.4 years old). Left ventricle samples were excised and processed with less than 30 min cold ischaemic time and snap frozen (XpressBANK, Asterand Biosciences). Bioptic specimens were taken after informed consent disclosing future use for research. The investigation conformed to the principles outlined in the Helsinki Declaration and to the Italian laws and guidelines, and was authorized by local Ethics Committee (protocol #2438, 27/01/2009 and CE#85/int/2016 9/6/ 2016). 
RNA inhibition and overexpression
RNA in situ hybridization assay and immunohistochemistry
For RNA in situ hybridization assays (ISH) the QuantiGene ViewRNA system (Affymetrix) was used, and LV FFPE sections were treated as described previously. 10 For a more detailed description, see Supplementary material online. 
b-amyloid and BACE1 detection
Statistics
Continuous variables are expressed as mean ± standard error (SE). Gaussian distribution was tested by using the Kolmogorov-Smirnov test. For two group comparisons, Mann-Whitney test (two groups) or t-test (two groups) were used as appropriate. When comparing more than two groups, ANOVA approach with Tukey's multiple comparisons test was used. All tests were performed 2-sided and a P < _ 0.05 was considered as statistically significant. GraphPad Prism v. 4 .03 software (GraphPad Software Inc.) was used for statistical analysis.
Results
The deregulation of BACE1-AS/BACE1 couple in HF
To evaluate BACE1 and BACE1-AS involvement in HF, we measured by qPCR the levels of these transcripts in the LV of 18 ischaemic HF and 17 control subjects, matched for age and sex. Of note, myocardial biopsies were harvested from the nonischaemic portion of the LV (remote zone) in non end-stage HF patients, allowing to investigate the molecular mechanisms underpinning disease during its progression. Total RNA was extracted form left ventricle biopsies of HF patients and controls, quality checked (see Supplementary material online, Figure S1 ) and the gene expression levels of BACE1-AS were measured by qPCR. We found that BACE1-AS was upregulated more than two-fold in HF compared to controls ( Figure 1A) . In keeping with previous observations indicating concordant regulation, 11 also BACE1 levels were higher in HF patients compared to healthy individuals ( Figure 1A) . BACE1-AS is not the only antisense RNA of BACE1. Transcript AB488780 is transcribed from an intron of BACE1 gene in antisense direction and it completely overlaps exons 5 and 6 of BACE-1 11 (see Supplementary material online, Figure S2 ). Interestingly, AB488780 levels were also induced in failing hearts (see Supplementary material online, Figure S3A ). Likewise, qPCR primers detecting exons 1 and 2 of BACE1, missing in the shorter isoforms yielded similar results (see Supplementary material online, Figure S3B ), indicating that the transcripts of the whole BACE1 locus were increased in HF. Given the homology of BACE1 (77%) and BACE1-AS (54%) to their murine counterparts, we assayed whether they were deregulated also in a mouse model of ischaemic HF. Myocardial infarction (MI) was induced in mice by coronary artery ligation, and the levels of both BACE1 sense and antisense transcripts were measured after 1 month, when overt heart dysfunction is present. 20 We found that the expression of both transcripts increased in ischaemic mice ( Figure 1B) , and their levels directly correlated significantly ( Figure 1C ).
Ubiquitous expression of BACE1-AS in the heart
Next, we assessed the heart cell types expressing BACE1-AS RNA by in situ hybridization in LV sections. We found that virtually all myocardial cells expressed BACE1-AS RNA, indicating a ubiquitous expression ( Figure 2 , top panels). Accordingly, BACE1-AS expression was detected in cells positive for a-sarcomeric actin, a cardiomyocyte marker, on serial sections ( Figure 2 , mid panels). BACE1-AS RNA positivity of blood vessels was confirmed by in situ hybridization followed by immunohistochemical endothelial staining for CD31 on serial sections ( Figure 2 , bottom panels). No overt alterations in BACE1-AS distribution were observed in HF compared to control subjects. The specificity of BACE1-AS signals was confirmed by negative controls performed using a probe for DapB of B. subtilis (see Supplementary material online, Figure S4 ). Figure 2 also shows that BACE1-AS displayed a prevalently nuclear localization in the heart. This was confirmed in human aortic endothelial cells (HAOEC) cultured in vitro (see Supplementary material online, Figure S5 ).
BACE1-AS positively modulates BACE1 mRNA expression
We explored whether BACE1-AS expression affected BACE1 levels in cells of the cardiovascular system.
As found before in other cell systems, 11, 12 BACE1-AS overexpression in HAOEC and HL-1 cells (see Supplementary material online, Figure  S6A and B) resulted in the concordant increase of BACE1 mRNA in both endothelial and cardiomyocyte cells ( Figure 3A) . Conversely, when BACE1-AS was inhibited by transfection of relevant LNA-GapmeRs in HAOEC or HL-1 (see Supplementary material online, Figure S6C and D), BACE1 mRNA expression decreased ( Figure 3B) . This was unlikely due to unspecific off-target effects, since BACE1/BACE1-AS concordant regulation was observed using independent LNA-GapmeRs as well (see Supplementary material online, Figure S6C and D). Next, we explored whether BACE1/BACE1-AS concordant regulation was also observed in response to physio-pathologically relevant stimuli. When HAOEC cells were exposed to either serum starvation or hypoxia, both stressors elicited the paired increase BACE1 and BACE1-AS ( Figure 3C and D) .
BACE1 and b-amyloid protein expressions are modulated by BACE1-AS
We tested whether BACE1-AS modulation also induced a concordant regulation of BACE1 protein.
Immunocytochemistry experiments showed that BACE1 was readily detectable in both endothelial cells ( Figure 4 ) and cardiomyocytes (see Supplementary material online, Figure S7 ), displaying a cytoplasmic punctuated pattern, compatible with the expected endosomal and trans-Golgi localization. 21 BACE1-AS RNA blocking reduced BACE1 protein expression ( Figure 4 and see Supplementary material online, Figure S7A , I-II) and, conversely, the overexpression of both BACE1-AS and BACE1 RNAs triggered the increase of BACE1 protein level ( Figure 4F and I). These observations further confirmed the regulation of BACE1 expression by BACE1-AS, not only at the mRNA but also at the protein level. Next, we tested whether BACE1-AS levels also regulated the accumulation of b-amyloid in vascular cells. Figure 5 and Supplementary material online, Figure S7A show that b-amyloid was readily detectable in both endothelial cells and cardiomyocytes, displaying a cytoplasmic dotted pattern, compatible with the expected endosomal localization. 21 BACE1-AS blocking by LNA-Gapmer induced the decrease of b-amyloid protein expression in both cell types ( Figure 5B and see Supplementary material online, Figure S7A , III-IV). Conversely, BACE1-AS overexpression in HAOEC induced its increase ( Figure 5F and I).
Increased expression of BACE1 and b-amyloid proteins in HF patients
Since in vitro data showed that increased levels of BACE1-AS induced BACE1 and b-amyloid accumulation, we tested by immunohistochemistry whether increased levels of these proteins were also present in the myocardium of HF patients. We found that BACE1 displayed a ubiquitous, punctuated staining ( Figure 6 ), and many cells had a perinuclear or a membrane accumulation ( Figure 6B and see Supplementary material online, Figure S8A) ; structures highly resembling blood vessels were positive too (see Supplementary material online, Figure S8B) .
When b-amyloid was assayed, it also showed a ubiquitous and diffuse pattern, compatible with intracellular b-amyloid oligomers ( Figure 6F) . Certain patients exhibited a prominent staining in blood vessels or in the nuclear/perinuclear area (see Supplementary material online, Figure S9) . No large extracellular staining, similar to the amyloid plaques found in Alzheimer's disease brains, was observed.
A weaker staining was observed for both BACE1 and b-amyloid in control hearts ( Figure 6A, D, E, and H) , in keeping with gene expression 
data (Figure 1) . Control stainings ( Figure 6C and G) , as expected, did not show any positivity; however, both control and HF sections displayed lipofuscin aggregates, recognized for their peculiar light yellow staining ( Figure 6C and G, red arrows) and their bright autofluorescence (not shown). 22 b-amyloid staining was performed by using a sequence-specific antibody. To corroborate our findings, we tested the presence of pre-amyloid oligomers (PAO) using a conformational antibody (anti-PAO). 23, 24 When failing heart sections were assayed, a diffuse staining, with a dotted pattern in certain cells, was observed (see Supplementary material online, Figure S10 ). Although other PAOgenic proteins might also contribute to PAO positivity, 25 these results are in agreement with the presence of b-amyloid peptides in HF myocardium.
Given the myocardial accumulation of b-amyloid in the heart of HF patients and the increased b-amyloid 1-40 blood levels observed in high risk coronary artery disease patients, 18 we tested b-amyloid 1-40 and 1-42 protein levels in plasma samples from ischaemic HF and healthy individuals. b-amyloid 1-42 was barely detectable in both HF and control plasmas and did not seem to change with disease ( Figure 6I) . Conversely, b-amyloid 1-40 was detectable in both groups and its concentration was significantly increased in HF patients ( Figure 6I ).
BACE1-AS and b-amyloid influence on EC transcriptome
To evaluate the importance of the BACE1-AS/BACE1/b-amyloid pathway, the effects on the transcriptome of BACE1-AS overexpression and Figure 4I shows quantification of BACE1 by ELISA in HAOEC cells overexpressing BACE1-AS or vector alone (n = 4; *P < _ 0.05, **P < _ 0.01, ***P < _ 0.001). All statistical significances were calculated against relevant controls: CTR GapmeR in panel C and VECTOR ALONE in panels H and I. of b-amyloid stimulation were assessed. To this aim, HAOEC cells were transduced with lentiviral vectors expressing BACE1-AS or were stimulated by 400 nM b-amyloid 1-40 peptide administration. Gene expression levels were then measured by microarray for BACE1-AS engineered cells and by RNA-Sequencing for b-amyloid stimulated cells, and differential expression was determined for both groups. When compared, the two sets of modulated genes displayed a significant overlap with 1326 mRNAs in common between the two stimuli (see Supplementary material online, Figure S11 ), of which 93.5% displayed a concordant regulation (X 2 test P < 10 -7
). After qPCR validation (data nor shown), the analysis of the enriched biological process of these 1326 differentially expressed genes by both Enrichr and WebGestalt tools indicated several categories relevant for cardiovascular physiopathology, including 'apoptosis', 'DNA damage response', 'cell cycle and proliferation', 'TGFb-, TNFa-, p38-EGFR-signalling', 'metabolism'. Categories linked to the ubiquitin proteasome system, that is related to proteotoxicity, were enriched as well (see Supplementary material online, Figure S11 and for details, see Supplementary material online, Table S2 ).
b-amyloid peptides are toxic to both endothelial cells and cardiomyocytes
The transcriptomic analysis of BACE1-AS overexpressing or of b-amyloid treated cells indicated a toxic role of b-amyloid accumulation in cardiovascular cells. Thus, we tested the effect of the administration of b-amyloid 1-40 and 1-42 peptides, the most frequent isoforms of b-amyloid, to HAOEC cells and to HL-1 mouse cardiomyocyte cells cultured in low serum medium (Figure 7) . We found that both b-amyloid 1-40 and 1-42 peptide administration decreased the number of both endothelial cells ( Figure 7A ) and cardiomyocytes ( Figure 7B) . To corroborate these data in human cardiomyocytes, induced pluripotent stem (iPS) cells differentiated to cardiomyocytes were used. Upon b-amyloid 1-40 administration, the number of FACS sorted Troponin-2 positive cells decreased significantly ( Figure 7C ). Figure 5I shows quantification of b-amyloid by ELISA in HAOEC cells overexpressing BACE1-AS or vector alone (n = 4; *P < _ 0.05, **P < _ 0.01, ***P < _ 0.001). All statistical significances were calculated against relevant controls: CTR GapmeR in panel C and VECTOR ALONE in panels H and I. 
Next, we tested whether a similar effect was obtained by BACE1-AS overexpression. Figure 7D shows that the viability of HAOEC overexpressing BACE1-AS decreased after 72 h in low-serum medium ( Figure 7D) . The cell death increase induced by BACE1-AS was prevented upon BACE1 silencing, demonstrating that BACE1-AS toxicity, at least in part, was mediated by BACE1.
As expected, ELISA assays showed that b-amyloid 1-40 and BACE1 protein levels were reduced in BACE1 silenced cells (see Supplementary material online, Figure S12) .
During the process of apoptosis, DNA fragmentation occurs following the activation of endonucleases. 26 Both b-amyloid 1-40 stimulation ( Figure 7E ) and BACE1-AS overexpression ( Figure 7F ) led to DNA fragmentation increase in HAOEC cells, suggesting the activation of the apoptosis pathway. These data suggest that the deregulation of BACE1-AS/BACE1/ b-amyloid pathway has a detrimental effect on the cardiovascular system.
Discussion
BACE1-AS has been connected to Alzheimer's neurodegenerative disease through its related coding gene BACE1. 11 We found that both BACE1-AS and BACE1 transcripts were upregulated in the LV of HF patients. Moreover, BACE1-AS RNA and BACE1 protein were expressed both in vascular tissue and in cardiomyocytes, suggesting a pervasive role in the heart as in the brain. 11, 12, 27 Intriguingly, a rat model of ischaemic HF displays increased BACE1 expression in the brain, and b-amyloid expression is increased in Alzheimer's disease patients suggesting a possible systemic increase of BACE1/b-amyloid. 28, 29 While, to the best of our knowledge, this is the first report on the coordinated dysregulation of BACE1 sense and antisense transcripts in the heart, the involvement of BACE1 and b-amyloid in diseases different from Alzheimer's has been observed before. Indeed, BACE1-AS, BACE1, and b-amyloid accumulate in skeletal muscles of patients affected by sporadic inclusion-body myositis. [30] [31] [32] Additionally, b-amyloid has also 18 measured the level of b-amyloid 1-40 peptide in plasma samples of two independent cohorts of stable coronary heart disease, and demonstrated that it was independently associated with the extent of atherosclerosis, improving the risk stratification for death. Accordingly, increased b-amyloid 1-40 was observed also in the patient group we analysed. Taken together, these data indicate a broad role of the BACE1/ BACE1-AS/b-amyloid axis in human diseases. We found that BACE1-AS modulation in both endothelial and cardiomyocyte cells elicited a concordant regulation of the BACE1 transcript. Accordingly, stress stimuli such as growth factor deprivation and hypoxia increased both BACE1 and BACE1-AS transcripts. These findings are in keeping with previous observations in other cell systems, 11, 27 where it was found that miR-485-5p and BACE1-AS compete for binding within the same region of the BACE1 mRNA. 12 A similar mechanism is likely present also in cardiovascular cells. However, the largely nuclear distribution of BACE1-AS suggests that epigenetic regulatory mechanisms may also play a role. 4, 35 The paradigm of Alzheimer's disease pathogenesis postulates that the accumulation of b-amyloid fibrils in extracellular plaques is the primary pathogenic event.
14 However, more recent evidence indicates that the insoluble aggregates of b-amyloid fibrils may not be inherently pathogenic, while the soluble intermediates of fibril formation, known as PAO, seem to be toxic. 36 PAO soluble oligomers have a conformation-dependent protein structure in common, regardless of protein of origin and can be detected by conformation-specific antibodies. 37 In keeping with our data, PAO oligomers have been found in animal models of HF as well as in human HF. [23] [24] [25] [38] [39] [40] Indeed, cardiomyocytes of patients affected by human dilated and hypertrophic cardiomyopathies expressed toxic PAO, indicating that intrasarcoplasmic amyloidosis might be a prevalent contributor to cardiac disease. 40 In an animal model, Pattison and co-workers 23 found that polyglutamine PAO expression led to HF and intracellular PAO accumulation triggered cardiomyocyte death. These 23,40 and other studies 23, 24, 38, 39 investigating pre-amyloid deposits in heart tissue employed a conformation-specific antibody, namely, an antibody that reacts with oligomers generated from all types of amyloidogenic proteins and peptides, such as a-synuclein, polyglutamine repeats and prions, as well as b-amyloids. 37 Instead, we showed cardiac stainings using a sequence-specific antibody, which recognizes the b-amyloid peptide only, thus linking the dysregulation of BACE1/BACE1-AS axis to the accumulation of b-amyloid peptide into the heart. We were unable to compare anti-b-amyloid and anti-PAO stainings directly. However, the distribution patterns might not be fully overlapping, in keeping with data implicating multiple PAO-genic proteins in HF. . (E and F) HAOEC were cultured in low growth factor medium and stimulated with 400 nM b-amyloid 1-40 or DMSO alone, for 48 hr (E; n = 9); alternatively, HAOEC were transduced with BACE1-AS or vector alone and exposed to low-growth factor medium for 72 hr (n = 7). DNA fragmentation was measured and the absorbance of labelled 3' ends was expressed as ratio vs. controls. All the statistical significances were calculated vs. relevant controls, as indicated (*P < _ 0.05, **P < _ 0.01, ***P < _ 0.001).
Increased BACE1-AS long noncoding RNA and b-amyloid levels . Intriguingly, we did not observe extracellular b-amyloid staining plaques in the LV of HF patients, but rather an intracellular staining, in keeping with the observation that b-amyloid is produced mainly in the endosomes. 21 This could be particularly relevant, given that the ability of amyloid oligomers to interact with different membranes has been proposed as a leading mechanism for their toxicity. 25 The analysis of the transcriptomic changes induced by BACE1-AS overexpression and b-amyloid administration in HAOEC provided a common signature of 1326 differentially deregulated mRNAs. The analysis of the enriched biological processes indicated a potential toxic role of b-amyloid accumulation in vascular cells. These data are in agreement with the toxic effect of b-amyloid in neuronal cells and with the pathogenic role of PAO also in cardiovascular diseases. 25 Thus, we evaluated the cellular effects of b-amyloids administration. We showed that both b-amyloid 1-40 and 1-42 were toxic to endothelial cells as well as to both human and mouse cardiomyocytes, and that bamyloid induced apoptosis. Accordingly, a similar pro-apoptotic effect was induced by BACE1-AS overexpression in a BACE1-dependent manner, demonstrating that BACE1-AS toxicity, at least in part, was mediated by BACE1.
In keeping with our findings, Zhang and co-workers 41 reported the toxic effects of a shorter b-amyloid peptide, aa 25-35, in isolated rat cardiac myocytes with impact on cytoskeleton assembly and on cardiomyocytes apoptosis caused by ER stress. Previous studies indicated b-amyloid 1-42 as more toxic than b-amyloid 1-40 in brain ECs. [42] [43] [44] We did not reproduce this difference, possibly due to differences in the experimental conditions and in the origin of ECs used. Given the pro-apoptotic effect of the BACE1-AS/b-amyloid couple, it is tempting to interpret BACE1/BACE1-AS induction and b-amyloid accumulation in failing hearts as exclusively maladaptive responses. However, the scenario might be more complex, In fact, b-amyloid peptides seem to be involved in cholesterol transport, stimulation of adhesion and neurite growth, and synaptic activity 45 and BACE1 ko mice have several peripheral and central nervous system defects and retinal damage. 21 Furthermore, many substrates different than b-amyloid have been identified, 21 including neuregulin 1 (NRG1), 46 voltage gated sodium channels (Na v ), 47 Vascular Endothelial Growth Factor receptor VEGFR1, 48 Notch1-ligand Jagged1, 49 and cell adhesion molecule L1-like (CHL1). 50 Albeit the studies performed so far were focused on the nervous system, many of these substrates may have a relevant function in the cardiovascular system as well. The autophagic-lysosomal pathway and the ubiquitin-proteasome are two major pathways responsible for degradation of most cellular proteins. Alterations of these proteolytic functions are associated with the accumulation of proteotoxic species in several cardiomyopathies. 51 Interestingly, the overlapping of transcriptomic changes induced by b-amyloid and BACE1-AS indicated the ubiquitin-dependent protein catabolic process among the enriched biological processes (see Supplementary material online, Table S2 ). The potential interaction between the dysregulation of the BACE1-AS/BACE1 axis and autophagic and proteasomal systems might also play a role in b-amyloid accumulation. Future investigations of BACE1-AS regulation and functions in healthy and diseased hearts are needed. However, these data suggest the implication of noncoding RNAs in the complex scenario of proteotoxicity in cardiac dysfunction. Additionally, b-amyloid accumulation in failing hearts indicate the hypothesis that brain and heart diseases might share BACE1-AS/BACE1 axis in certain steps of their pathogenic cascades.
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